Circulating <small.letters>s</small.letters>CD138 and Some Angiogenesis-Involved Cytokines Help to Anticipate the Disease Progression of Early-Stage <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>B</mml:mi></mml:math>-Cell Chronic Lymphocytic Leukemia

Wołowiec, Dariusz; Dybko, Jarosław; Wróbel, Tomasz; Urbaniak-Kujda, Donata; Jaźwiec, Bożena; Tomaszewska-Toporska, Beata; Kapelko-Słowik, Katarzyna; Potoczek, Stanisław; Kuliczkowski, Kazimierz

doi:https://doi.org/10.1155/MI/2006/42394

Mediators of Inflammation

On this page

Abstract References Copyright Related Articles

Research Communication | Open Access

Volume 2006 | Article ID 042394 | https://doi.org/10.1155/MI/2006/42394

Circulating sCD138 and Some Angiogenesis-Involved Cytokines Help to Anticipate the Disease Progression of Early-Stage B-Cell Chronic Lymphocytic Leukemia

Dariusz Wołowiec,¹Jarosław Dybko,¹Tomasz Wróbel,¹Donata Urbaniak-Kujda,¹Bożena Jaźwiec,¹Beata Tomaszewska-Toporska,¹Katarzyna Kapelko-Słowik,¹Stanisław Potoczek,¹and Kazimierz Kuliczkowski¹

Received04 Dec 2005

Revised12 Mar 2006

Accepted13 Mar 2006

Published11 Apr 2006

Abstract

Syndecan-1 (CD138) is a transmembrane heparin sulfate proteoglycan expressed on distinct stages of differentiation of B-lymphoid cells. Its prognostic value in B-cell chronic lymphocytic leukemia (B-CLL) has not been evaluated so far. The serum concentration of sCD138 and some angiogenesis-involved cytokines: vascular endothelial growth factor (VEGF), basis fibroblast growth factor (bFGF), and endostatin were studied in 52 previously untreated patients with B-CLL. We found that bFGF and sCD138 levels were significantly higher in B-CLL patients than in controls. In patients with sCD138 level or endostatin level below the median value the lymphocyte count was higher than in patients with serum level of those cytokines above the median value. In patients with progressive disease bFGF level was significantly higher and sCD138 level significantly lower than in patients with stable one. Moreover, high sCD138 level was associated with longer lymphocyte doubling-free survival, and, on the limit of statistical significance, a high endostatin level was associated with shorter progression-free survival. We conclude that serum sCD138 level is increased in early stage B-CLL patients and may have a positive prognostic value as to the dynamics of the disease.

References

E Ruoslahti and Y Yamaguchi, “Proteoglycans as modular of growth factor activities,” Cell, vol. 64, pp. 867–869, 1991.
View at: Google Scholar
M Bernfield, R Kokenyesi, M Kato et al., “Biology of the sydecans: a family of four transmembrane heparan sulphate proteoglycans,” Annual Review of Cell Biology, vol. 8, pp. 365–393, 1993.
View at: Google Scholar
K Elenius and M Jalkanen, “Function of the syndecans: a family of cell surface proteoglycans,” Journal of Cell Science, vol. 107, no. 11, pp. 2975–2982, 1994.
View at: Google Scholar
R D Sanderson, P Lalor, and M Bernfield, “B lymphocytes express and lose syndecan at specific stages of differentiation,” Cell Regulation, vol. 1, no. 1, pp. 27–35, 1989.
View at: Google Scholar
M V Dhodapkar, T Kelly, A Theus, A B Athota, B Barlogie, and R D Sanderson, “Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma,” British Journal of Haematology, vol. 99, no. 2, pp. 368–371, 1997.
View at: Google Scholar
M V Dhodapkar, E Abe, A Theus et al., “Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation,” Blood, vol. 91, no. 8, pp. 2679–2688, 1998.
View at: Google Scholar
R C Ridley, H Xiao, H Hata, J Woodlif, J Epstein, and R D Sanderson, “Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen,” Blood, vol. 81, no. 3, pp. 767–774, 1993.
View at: Google Scholar
C Seidel, A Sundan, M Hjorth et al., “Serum syndecan-1: a new independent prognostic marker in multiple myeloma,” Blood, vol. 95, no. 2, pp. 388–392, 2000.
View at: Google Scholar
A Sebestyen, L Berczi, R Mihalik, S Paku, A Matolcsy, and L Kopper, “Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas,” British Journal of Haematology, vol. 104, no. 2, pp. 412–419, 1999.
View at: Google Scholar
T E Witzig, T Kimlinger, M Stenson, and T Therneau, “Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia,” Leukemia and Lymphoma, vol. 31, no. 1-2, pp. 167–175, 1998.
View at: Google Scholar
B D Cheson, J M Bennett, M Grever et al., “National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment,” Blood, vol. 87, no. 12, pp. 4990–4997, 1996.
View at: Google Scholar
F Bertolini, M Paolucci, F Peccatori et al., “Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma,” British Journal of Haematology, vol. 106, no. 2, pp. 504–509, 1999.
View at: Google Scholar
C Basilico and D Moscatelli, “The FGF family of growth factors and oncogenes,” Advances in Cancer Research, vol. 59, pp. 115–165, 1992.
View at: Google Scholar
A Bikfalvi and Z C Han, “Angiogenic factors are hematopoietic growth factors and vice versa,” Leukemia, vol. 8, no. 3, pp. 523–529, 1994.
View at: Google Scholar
A Konig, T Menzel, S Lynen et al., “Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis,” Leukemia, vol. 11, no. 2, pp. 258–265, 1997.
View at: Google Scholar
O Bairey, Y Zimara, M Shaklai, and E Rabizadeh, “Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia,” British Journal of Haematology, vol. 113, no. 2, pp. 400–406, 2001.
View at: Google Scholar
S Duensing and J Atzpodien, “Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia,” Blood, vol. 85, no. 7, pp. 1978–1979, 1995.
View at: Google Scholar
I Christiansen, C Gidlof, A Wallgren, B Simonsson, and T H Tottermann, “Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers,” Blood, vol. 84, no. 9, pp. 3010–3016, 1994.
View at: Google Scholar
S Molica, A Vacca, D Ribatti et al., “Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia,” Blood, vol. 100, no. 9, pp. 3344–3351, 2002.
View at: Google Scholar
S Molica, G Vitelli, D Levato, A Ricciotti, and G Digiesi, “Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia,” British Journal of Cancer, vol. 86, no. 1, pp. 31–35, 2002.
View at: Google Scholar
A Aguayo, H Kantarjian, T Manshouri et al., “Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes,” Blood, vol. 96, no. 6, pp. 2240–2245, 2000.
View at: Google Scholar
H Chen, A T Treeweeke, D C West et al., “In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells,” Blood, vol. 96, no. 9, pp. 3181–3187, 2000.
View at: Google Scholar
A R Kini, N E Kay, and L C Peterson, “Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia,” Leukemia, vol. 14, no. 8, pp. 1414–1418, 2000.
View at: Google Scholar
S Molica, G Vitelli, D Levato, G M Gandolfo, and V Liso, “Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia,” British Journal of Haematology, vol. 107, no. 3, pp. 605–610, 1999.
View at: Google Scholar
M O'Reilly, T Boehm, Y Shing et al., “Endostatin: an endogenous inhibitor of angiogenesis and tumor growth,” Cell, vol. 88, no. 2, pp. 277–285, 1997.
View at: Google Scholar
A L Feldman, H Pak, J C Yang, H R Jr Alexander, and S K Libutti, “Serum endostatin levels are elevated in patients with soft tissue sarcoma,” Cancer, vol. 91, no. 8, pp. 1525–1529, 2001.
View at: Google Scholar
A L Feldman, L Tamarkin, G F Paciotti et al., “Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer,” Clinical Cancer Research, vol. 6, no. 12, pp. 4628–4634, 2000.
View at: Google Scholar
M Yamagata, Y Shiratori, Y Dan et al., “Serum endostatin levels in patients with hepatocellular carcinoma,” Annals of Oncology, vol. 11, no. 6, pp. 761–762, 2000.
View at: Google Scholar
J Góra-Tybor, J Z Błoński, and T Robak, “Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia,” Mediators of Inflammation, vol. 12, no. 3, pp. 167–171, 2003.
View at: Google Scholar
R Lai, E Estey, Y Shen et al., “Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome,” Cancer, vol. 94, no. 1, pp. 14–17, 2002.
View at: Google Scholar

Copyright

Copyright © 2006 Dariusz Wołowiec et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

423

Downloads

658

Citations